Menu
Your Cart

About Us


Apostle Inc is a biotechnology company and a provider of innovative technologies and services for public health and life sciences. The company owns and operates its headquarters at: 3589 Nevada St, Pleasanton, CA 94566.

Apostle aims to develop best-in-class nucleic acid isolation and preservation technologies. Specifically, we aim to develop innovative technologies in the field of circulating free DNA (cfDNA), used in noninvasive prenatal testing (NIPT) and liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing cfDNA as a biomarker. Our innovations include Apostle MiniMax, a best-in-class and automatable solution to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform.

In addition, Apostle also provides the MiniGenomics product series, providing efficient, scalable, and reproducible isolation of high-quality genomic DNA and/or RNA from a variety of biological specimens. The Apostle MiniGenomics product series has contributed significantly to the flight against COVID-19 during the recent pandemic.

Apostle technologies have been widely applied in many world-class R&D studies, clinical laboratory settings, and public health response and surveillance. These applications have resulted in many high-profile scientific publications including Nature Medicine, Nature Communications, Science Translational Medicine, PNAS, etc. To date, the company's products have served over 20 million people, while we are continuing to improve our technologies and products to further our mission to benefit public health and life sciences.

Accreditations

Team - Scientific Advisory Board

Team - Management

All Publications

Apostle technologies have been cited or used by scientists from the following organizations. Click to read more when there is a publication.

Track Record of Publications

Recognitions

  • APR 10, 2023, Apostle MiniMax Technology is cited by a new independent clinical study  including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection, published in Nature Communications.
  • NOV 23, 2022, Apostle MiniMax Technology is cited by another independent clinical study demonstrating the successful clinical utility and validity of the circulating cell-free DNA (cfDNA) analysis for hepatocellular carcinoma (HCC) detection with high sensitivity and specificity, published in Science Translational Medicine.
  • AUG 18, 2022, Apostle MiniMax Technology is cited by a new independent clinical study, published in Nature Medicine by a joint clinical team from Gritstone, Columbia University Medical Center, Mayo Clinic, MSKCC, MD Anderson, showing “exploratory biomarker analyses showed decreased circulating tumor DNA (ctDNA) in patients with prolonged OS”.
  • JUN 14, 2022, Clinical Study Supports the Use of Liquid Biopsy for Early Diagnosis and Monitoring of Patients with Myeloid Neoplasms, Citing Apostle MiniMax Technology.  
  • APR 11, 2022, Apostle MiniMax Technology is cited by an independent clinical study, published in Nature Medicine, studying safety and tolerability of AAV8 delivery of a broadly neutralizing antibody. 
  • JAN 28, 2022, Performance of Apostle technology is independently validated in an independent study by scientists from Johns Hopkins University and University of Pittsburgh, published in SLAS Technology, showed that, "(Page 6, Figure 4) Most notably, the Apostle particles outperformed all others, achieving almost 2-fold higher recovery yields than the particles supplied in the X kit".
  • AUG 30, 2021, Apostle Inc Apostle Diagnostics Laboratory Receives Accreditation from College of American Pathologists.
  • APR 12, 2021, Apostle RNA Extraction Method is Included in a US FDA EUA Authorized SARS-CoV-2 Molecular Diagnostic Test: Fulgent COVID-19 by RT-PCT Test.
  • FEB 2, 2021, Apostle MiniMax Technology In Novel Liquid Biopsy Method for Detecting and Monitoring Colon Cancer, Published in PNAS.
  • SEPT 7, 2020, Apostle MiniEnrich Technology is Published in Royal Society of Chemistry’s Analyst.
  • MAY 24, 2019, Apostle Inc Completes Series A Financing Led by ShangBay Capital, Palo Alto, CA.
  • FEB 28, 2019, Apostle Inc. Enters Partnership with Beckman Coulter Life Sciences.
  • APR 3, 2018, Apostle is Elected into the Stanford University StartX Accelerator Program.

 

Apostle Diagnostics

Awards

StartX Med

Headquarters: 3589 Nevada St, Pleasanton, CA 94566

Headquarters: 3589 Nevada St, Pleasanton, CA 94566
Headquarters: 3589 Nevada St, Pleasanton, CA 94566
Headquarters: 3589 Nevada St, Pleasanton, CA 94566
All Publications
Contact Us
Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.